SPRY – ars pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver [Yahoo! Finance]
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label [Yahoo! Finance]
Form ARS ARS Pharmaceuticals, For: Dec 31
Form DEFA14A ARS Pharmaceuticals,
Form DEF 14A ARS Pharmaceuticals, For: Jun 24
Form SCHEDULE 13G/A ARS Pharmaceuticals, Filed by: BlackRock, Inc.
Form SCHEDULE 13G/A ARS Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.